Concentrations and molecular forms of human brain natriuretic peptide in plasma. 1992

H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
Department of Biochemistry, Japan.

Using a highly sensitive radioimmunoassay (RIA) system for human brain natriuretic peptide (BNP), immunoreactive (ir-) human BNP was found to be present in plasma, in addition to heart and brain tissue. Plasma concentrations of ir-BNP were 0.17-0.74 fmol/ml (mean: 0.35 fmol/ml) in normal young men, being about 1/17 of the plasma concentration of human atrial natriuretic peptide (ANP). In patients with heart disease, plasma concentration of ir-BNP increased about 100-fold (5.00-177.37 fmol/ml), being nearly comparable to that of ir-ANP, even though ANP concentration also increased about 7-fold. Two molecular forms of ir-BNP in plasma were identified as BNP-32 and gamma-BNP (pro-BNP), which are also found in cardiac atrium. In normal human plasma, gamma-BNP is the predominant molecular form, while the main form in cardiac atrium is BNP-32. These results suggest that biosynthesis and secretion of BNP are augmented in heart disease and that human BNP has a unique processing and metabolic system distinct from that of ANP.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002846 Chromatography, Affinity A chromatographic technique that utilizes the ability of biological molecules, often ANTIBODIES, to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Bioaffinity,Immunochromatography,Affinity Chromatography,Bioaffinity Chromatography
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D020097 Natriuretic Peptide, Brain A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. Brain Natriuretic Peptide,Nesiritide,B-Type Natriuretic Peptide,BNP Gene Product,BNP-32,Brain Natriuretic Peptide-32,Natrecor,Natriuretic Factor-32,Natriuretic Peptide Type-B,Type-B Natriuretic Peptide,Ventricular Natriuretic Peptide, B-type,BNP 32,Brain Natriuretic Peptide 32,Natriuretic Factor 32,Natriuretic Peptide Type B,Natriuretic Peptide, B-Type,Natriuretic Peptide, Type-B,Natriuretic Peptide-32, Brain,Peptide, Brain Natriuretic,Peptide-32, Brain Natriuretic,Type B Natriuretic Peptide,Ventricular Natriuretic Peptide, B type

Related Publications

H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
February 2002, Clinica chimica acta; international journal of clinical chemistry,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
August 2003, Clinica chimica acta; international journal of clinical chemistry,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
April 1995, Clinical nephrology,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
October 1992, Clinical chemistry,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
May 2007, Hypertension (Dallas, Tex. : 1979),
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
May 1991, Biochemical and biophysical research communications,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
June 2000, Pediatrics international : official journal of the Japan Pediatric Society,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
June 1993, British journal of biomedical science,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
July 1993, Clinical cardiology,
H Tateyama, and J Hino, and N Minamino, and K Kangawa, and T Minamino, and K Sakai, and T Ogihara, and H Matsuo
July 1995, Respiratory medicine,
Copied contents to your clipboard!